RNS60 Treatment Slows the Decline of Measures of Respiratory and Bulbar Function in a Phase 2 Trial in ALS

September 2022

The investigators of a Phase 2 clinical trial in 147 people with ALS at 22 clinical centers in Italy, led by the Mario Negri Institute in Milan, report that RNS60 treatment for 24 weeks resulted in a significantly slower decline of forced vital capacity (FVC), a measure of respiratory function, when compared to placebo. RNS60-treated trial participants also showed a significantly slower decline in the portion of the ALSAQ-40 quality-of-life scale that evaluates the ability of people with ALS to eat and drink, suggesting a possible effect on bulbar function. RNS60 treatment was well tolerated in the trial, with fewer dropouts in the RNS60 arm than in the placebo arm. The findings support further testing of RNS60 as a treatment for ALS.

Link to the article: Effect of RNS60 in Amyotrophic Lateral Sclerosis: a Phase II Multicentre, Randomized, Double-blind, Placebo-controlled Trial | Wiley Online Library